Publication | Closed Access

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study

Surgical OncologyNeoadjuvant Osimertinib FollowedMedicinePathologyBronchial NeoplasmCancer TreatmentPhase 2OncologyRadiation OncologyLung CancerMolecular OncologyCancer Growth